GlassScriptPhysician profile
Pauline Jacinto
NPI 1003131988
$2,495.89
in general payments reported to CMS, 2019-2025
15 companies · $147 in 2025
The $147 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $671 · 2021: $398 · 2022: $484 · 2023: $396 · 2024: $169 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $765.24 | 2019-2025 | |
| Viiv Healthcare Company | $672.43 | 2019-2024 | Dovato, Rukobia |
| Theratechnologies INC. | $229.32 | 2019-2022 | |
| Janssen Biotech, INC. | $208.81 | 2020-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $202.88 | 2019-2023 | Pifeltro, Delstrigo |
| Janssen Products, LP | $99.00 | 2020 | |
| Insmed, INC. | $97.22 | 2021-2025 | Arikayce |
| Abbvie INC. | $52.57 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $51.60 | 2023-2025 | Rebyota |
| La Jolla Pharmaceutical Company | $32.30 | 2024-2025 | Zevtera, Xerava |
| Paratek Pharmaceuticals, INC. | $23.59 | 2025 | Nuzyra |
| Actelion Pharmaceuticals US, INC. | $18.35 | 2019 | |
| Seqirus USA INC | $15.26 | 2025 | Flucelvax, Fluad |
| Melinta Therapeutics, LLC | $14.18 | 2024 | Rezzayo, Vabomere |
| Shionogi INC | $13.14 | 2024 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pauline Jacinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.